A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin

NCT06335134 · Completed

Last updated 2026-05-28

This study tests how the drug XW003 interacts with metformin, warfarin, rosuvastatin, or digoxin in healthy volunteers by measuring how the body processes metformin.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) treatment study

Participants 57 people

Who can join Ages 18–45 · all sexes Healthy volunteers accepted.

Timeline Started 2023-07 · est. completion 2024-06

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT06335134 ↗

Description as written by the study sponsor.

This is a study of a drug-drug interaction between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin

Treatments tested

XW003 injection also known as ecnoglutide Drug

Administered subcutaneously
Metformin Drug

Administered orally
Warfarin Drug

Administered orally
Rosuvastatin Drug

Administered orally
Digoxin Drug

Administered orally

Main thing measured	Pharmacokinetics of metformin: AUC0-inf
Sponsor	Hangzhou Sciwind Biosciences Co., Ltd.
Conditions studied	Healthy Volunteers
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06335134 ↗